• ≥ 18 years of age

• Patient diagnosed with CD for more than 6 months with histological confirmation available in his medical record.

• Indication for MRE based on routine clinical practice validated by the treating physician

• Any CD treatment will be authorized, such as biologicals (infliximab, adalimumab, vedolizumab, ustekinumab…), or immunomodulators (azathioprine, 6-mercaptopurine, methotrexate…).

• The subjects sign and date a written, informed consent form and any required privacy authorization prior to the initiation of the study.

• A subject can be enrolled into the study only if the grade of TH (assessed by the LRP) corresponding to the subject is not already fulfilled.